Can-Fite Biopharma (CANFY) Ltd. advanced to the highest in more than 20 months after Roth Capital Partners rated the Israeli developer of oral drugs a new buy with a price target of triple its ADR price. The shares of the company that is expecting results of studies in dry-eye syndrome and rheumatoid arthritis patients this quarter advanced 15 percent to 12.50 shekels, the highest level since Jan. 2012, at 2:59 p.m. in Tel Aviv. Volume was more than 11 times the daily three-month average.
Help employers find you! Check out all the jobs and post your resume.
